Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.24
ZTS's Cash to Debt is ranked lower than
85% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. ZTS: 0.24 )
Ranked among companies with meaningful Cash to Debt only.
ZTS' s Cash to Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.24 Max: N/A
Current: 0.24
Equity to Asset 0.14
ZTS's Equity to Asset is ranked lower than
96% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. ZTS: 0.14 )
Ranked among companies with meaningful Equity to Asset only.
ZTS' s Equity to Asset Range Over the Past 10 Years
Min: 0.14  Med: 0.20 Max: 0.65
Current: 0.14
0.14
0.65
Interest Coverage 8.19
ZTS's Interest Coverage is ranked lower than
69% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.94 vs. ZTS: 8.19 )
Ranked among companies with meaningful Interest Coverage only.
ZTS' s Interest Coverage Range Over the Past 10 Years
Min: 2.3  Med: 7.55 Max: 22.42
Current: 8.19
2.3
22.42
F-Score: 4
Z-Score: 3.40
M-Score: -2.41
WACC vs ROIC
8.14%
18.58%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 21.32
ZTS's Operating margin (%) is ranked higher than
83% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. ZTS: 21.32 )
Ranked among companies with meaningful Operating margin (%) only.
ZTS' s Operating margin (%) Range Over the Past 10 Years
Min: -4.53  Med: 15.74 Max: 19.73
Current: 21.32
-4.53
19.73
Net-margin (%) 7.11
ZTS's Net-margin (%) is ranked higher than
53% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. ZTS: 7.11 )
Ranked among companies with meaningful Net-margin (%) only.
ZTS' s Net-margin (%) Range Over the Past 10 Years
Min: -3.62  Med: 7.11 Max: 12.18
Current: 7.11
-3.62
12.18
ROE (%) 27.96
ZTS's ROE (%) is ranked higher than
91% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. ZTS: 27.96 )
Ranked among companies with meaningful ROE (%) only.
ZTS' s ROE (%) Range Over the Past 10 Years
Min: 11.26  Med: 20.30 Max: 51.8
Current: 27.96
11.26
51.8
ROA (%) 4.95
ZTS's ROA (%) is ranked higher than
57% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. ZTS: 4.95 )
Ranked among companies with meaningful ROA (%) only.
ZTS' s ROA (%) Range Over the Past 10 Years
Min: 4.68  Med: 7.86 Max: 8.87
Current: 4.95
4.68
8.87
ROC (Joel Greenblatt) (%) 23.70
ZTS's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. ZTS: 23.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ZTS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 24.65  Med: 29.85 Max: 36.32
Current: 23.7
24.65
36.32
Revenue Growth (3Y)(%) 3.10
ZTS's Revenue Growth (3Y)(%) is ranked lower than
60% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. ZTS: 3.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ZTS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.55 Max: 8.4
Current: 3.1
0
8.4
EBITDA Growth (3Y)(%) -2.80
ZTS's EBITDA Growth (3Y)(%) is ranked lower than
69% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. ZTS: -2.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ZTS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 7.85 Max: 36.2
Current: -2.8
0
36.2
EPS Growth (3Y)(%) -8.20
ZTS's EPS Growth (3Y)(%) is ranked lower than
73% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. ZTS: -8.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ZTS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 12.55 Max: 66
Current: -8.2
0
66
» ZTS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

ZTS Guru Trades in Q2 2015

Richard Perry 2,000,000 sh (New)
Steven Cohen 4,246,900 sh (+2882.37%)
Paul Tudor Jones 30,630 sh (+248.07%)
Louis Moore Bacon 95,000 sh (+72.73%)
Mario Gabelli 695,142 sh (+13.07%)
Ruane Cunniff 151,149 sh (+8.01%)
Pioneer Investments 2,881,279 sh (+0.06%)
Bill Ackman 41,823,145 sh (unchged)
Caxton Associates Sold Out
John Keeley 60,874 sh (-1.59%)
Jim Simons 1,510,800 sh (-17.12%)
Vanguard Health Care Fund 5,115,837 sh (-17.16%)
George Soros 2,744,635 sh (-33.17%)
First Eagle Investment 508,942 sh (-37.97%)
Robert Olstein 20,000 sh (-85.82%)
» More
Q3 2015

ZTS Guru Trades in Q3 2015

Jana Partners 3,894,424 sh (New)
Paul Tudor Jones 48,955 sh (+59.83%)
Richard Perry 3,000,200 sh (+50.01%)
George Soros 3,520,997 sh (+28.29%)
Louis Moore Bacon 115,000 sh (+21.05%)
Pioneer Investments 3,288,456 sh (+14.13%)
Steven Cohen 4,788,800 sh (+12.76%)
Ruane Cunniff 156,094 sh (+3.27%)
Bill Ackman 41,823,145 sh (unchged)
Robert Olstein Sold Out
First Eagle Investment Sold Out
John Keeley 58,474 sh (-3.94%)
Vanguard Health Care Fund 4,804,337 sh (-6.09%)
Mario Gabelli 615,801 sh (-11.41%)
Jim Simons 886,200 sh (-41.34%)
» More
Q4 2015

ZTS Guru Trades in Q4 2015

Pioneer Investments 3,457,394 sh (+5.14%)
Bill Ackman 41,823,145 sh (unchged)
Louis Moore Bacon Sold Out
Richard Perry Sold Out
Jana Partners Sold Out
Ruane Cunniff 151,537 sh (-2.92%)
Mario Gabelli 592,363 sh (-3.81%)
George Soros 3,386,512 sh (-3.82%)
Steven Cohen 4,414,600 sh (-7.81%)
Paul Tudor Jones 44,407 sh (-9.29%)
Vanguard Health Care Fund 4,251,727 sh (-11.50%)
John Keeley 35,902 sh (-38.60%)
Jim Simons 283,400 sh (-68.02%)
» More
Q1 2016

ZTS Guru Trades in Q1 2016

First Eagle Investment 2,812,702 sh (New)
Vanguard Health Care Fund Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Zoetis Inc

Bill Ackman Comments on Zoetis Inc. - Dec 16, 2015

Zoetis, Inc. (NYSE:ZTS)

On November 3rd, Zoetis reported another strong quarter. Operational revenue grew 9% and operational adjusted net income grew 31%, excluding the impact of foreign exchange. Growth was driven by strong performance in the U.S. livestock business, the integration of the Abbott Animal Health business that was acquired in the first quarter of 2015, and growth in recently launched products in the companion animal sector. Reported revenue of $1.2 billion was flat year-on-year, while reported EPS of $0.38 represented a 15% increase over third quarter 2014 reported EPS.

Adjusted diluted net income per share, which excludes purchase accounting adjustments and certain one-time costs, was $0.50. This is an increase of 22% compared to third quarter 2014, and significantly in excess of the Wall Street consensus adjusted EPS estimate of $0.40 per share.

Management continues to demonstrate its expense discipline. Operating expenses grew 3% while operational revenue grew 9% excluding the impact of foreign exchange. Management reaffirmed its commitment to meet or exceed the previously announced $300 million expense reduction target by 2017.

During the quarter, the company announced the $765 million acquisition of PHARMAQ, the global leader in vaccines for aquaculture, or farmed fish. Aquaculture is the fastest growing segment of the global animal health industry and is the only segment in which Zoetis had limited presence. The PHARMAQ acquisition provides a market-leading portfolio of vaccines and pharmaceuticals for farmed fish as well as a late-stage development pipeline anticipated to deliver important new vaccines and next-generation parasiticides in the near term. PHARMAQ is a good strategic fit with Zoetis, and provides another pillar for long-term growth. The company believes this acquisition will enjoy a long period of sustainable growth in revenue, profits, and cash flow when added into its business.

From Bill Ackman (Trades, Portfolio)'s Pershing Square Holdings third quarter 2015 letter to shareholders.

Check out Bill Ackman latest stock trades

Bill Ackman Comments on Zoetis Inc. - Sep 11, 2015

Zoetis, Inc. (NYSE:ZTS)



Second quarter earnings exceeded analyst expectations. Management raised 2015 earnings guidance modestly for the year. Revenue growth in the quarter was impressive. Organic revenue adjusted for foreign exchange was 9%. Approximately 80% of revenue growth in the quarter is attributable to volume growth of recently launched and existing products. Operating expenses, adjusted for foreign exchange, rose only 1%, despite an 11% increase in revenue. Management announced significant progress in its R&D portfolio, including advances in new product innovation and improvements to existing products.



In May, Zoetis announced a large cost restructuring program. Management has begun to take its first steps towards achieving this plan and believes it is on track to deliver its target of at least $300 million of savings, which will increase Zoetis’ operating profit margin from 25% in 2014 to 34% in 2017 according to the company’s second quarter conference call. Thereafter, management expects a combination of continued cost discipline, strong revenue growth, and execution of management’s supply chain efficiency program will result in continuing improvements in operating profit margins.



From Pershing Square's semi-annual 2015 report.



Check out Bill Ackman latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 70.95
ZTS's P/E(ttm) is ranked lower than
83% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.66 vs. ZTS: 70.95 )
Ranked among companies with meaningful P/E(ttm) only.
ZTS' s P/E(ttm) Range Over the Past 10 Years
Min: 27.31  Med: 37.97 Max: 71.11
Current: 70.95
27.31
71.11
Forward P/E 20.92
ZTS's Forward P/E is ranked lower than
67% of the 69 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.86 vs. ZTS: 20.92 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 70.95
ZTS's PE(NRI) is ranked lower than
84% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.62 vs. ZTS: 70.95 )
Ranked among companies with meaningful PE(NRI) only.
ZTS' s PE(NRI) Range Over the Past 10 Years
Min: 27.31  Med: 37.97 Max: 71.53
Current: 70.95
27.31
71.53
Price/Owner Earnings (ttm) 145.72
ZTS's Price/Owner Earnings (ttm) is ranked lower than
86% of the 259 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.02 vs. ZTS: 145.72 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ZTS' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 73.67  Med: 133.52 Max: 166.91
Current: 145.72
73.67
166.91
P/B 22.44
ZTS's P/B is ranked lower than
97% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. ZTS: 22.44 )
Ranked among companies with meaningful P/B only.
ZTS' s P/B Range Over the Past 10 Years
Min: 12.62  Med: 18.28 Max: 24.4
Current: 22.44
12.62
24.4
P/S 5.15
ZTS's P/S is ranked lower than
68% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. ZTS: 5.15 )
Ranked among companies with meaningful P/S only.
ZTS' s P/S Range Over the Past 10 Years
Min: 3.11  Med: 3.90 Max: 5.25
Current: 5.15
3.11
5.25
PFCF 55.04
ZTS's PFCF is ranked lower than
72% of the 192 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.79 vs. ZTS: 55.04 )
Ranked among companies with meaningful PFCF only.
ZTS' s PFCF Range Over the Past 10 Years
Min: 25.69  Med: 45.52 Max: 90.29
Current: 55.04
25.69
90.29
POCF 36.45
ZTS's POCF is ranked lower than
77% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.79 vs. ZTS: 36.45 )
Ranked among companies with meaningful POCF only.
ZTS' s POCF Range Over the Past 10 Years
Min: 21.62  Med: 31.61 Max: 41.91
Current: 36.45
21.62
41.91
EV-to-EBIT 41.47
ZTS's EV-to-EBIT is ranked lower than
78% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.51 vs. ZTS: 41.47 )
Ranked among companies with meaningful EV-to-EBIT only.
ZTS' s EV-to-EBIT Range Over the Past 10 Years
Min: 20.8  Med: 26.35 Max: 42.1
Current: 41.47
20.8
42.1
EV-to-EBITDA 31.95
ZTS's EV-to-EBITDA is ranked lower than
75% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. ZTS: 31.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZTS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 16.7  Med: 20.95 Max: 32.4
Current: 31.95
16.7
32.4
PEG 4.09
ZTS's PEG is ranked lower than
72% of the 279 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.91 vs. ZTS: 4.09 )
Ranked among companies with meaningful PEG only.
ZTS' s PEG Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 9973.9
Current: 4.09
0
9973.9
Current Ratio 2.15
ZTS's Current Ratio is ranked lower than
56% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. ZTS: 2.15 )
Ranked among companies with meaningful Current Ratio only.
ZTS' s Current Ratio Range Over the Past 10 Years
Min: 2.15  Med: 2.55 Max: 3.19
Current: 2.15
2.15
3.19
Quick Ratio 1.33
ZTS's Quick Ratio is ranked lower than
65% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. ZTS: 1.33 )
Ranked among companies with meaningful Quick Ratio only.
ZTS' s Quick Ratio Range Over the Past 10 Years
Min: 1.33  Med: 1.46 Max: 2
Current: 1.33
1.33
2
Days Inventory 290.74
ZTS's Days Inventory is ranked lower than
92% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. ZTS: 290.74 )
Ranked among companies with meaningful Days Inventory only.
ZTS' s Days Inventory Range Over the Past 10 Years
Min: 117.43  Med: 281.16 Max: 289.4
Current: 290.74
117.43
289.4
Days Sales Outstanding 71.77
ZTS's Days Sales Outstanding is ranked higher than
52% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. ZTS: 71.77 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZTS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 71.77  Med: 75.10 Max: 91.07
Current: 71.77
71.77
91.07
Days Payable 61.53
ZTS's Days Payable is ranked lower than
59% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.22 vs. ZTS: 61.53 )
Ranked among companies with meaningful Days Payable only.
ZTS' s Days Payable Range Over the Past 10 Years
Min: 47.28  Med: 61.65 Max: 110.66
Current: 61.53
47.28
110.66

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.74
ZTS's Dividend Yield is ranked lower than
73% of the 565 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.56 vs. ZTS: 0.74 )
Ranked among companies with meaningful Dividend Yield only.
ZTS' s Dividend Yield Range Over the Past 10 Years
Min: 0.21  Med: 0.67 Max: 0.94
Current: 0.74
0.21
0.94
Dividend Payout 0.49
ZTS's Dividend Payout is ranked lower than
56% of the 371 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.35 vs. ZTS: 0.49 )
Ranked among companies with meaningful Dividend Payout only.
ZTS' s Dividend Payout Range Over the Past 10 Years
Min: 0.19  Med: 0.25 Max: 0.49
Current: 0.49
0.19
0.49
Forward Dividend Yield 0.81
ZTS's Forward Dividend Yield is ranked lower than
72% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. ZTS: 0.81 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.74
ZTS's Yield on cost (5-Year) is ranked lower than
77% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.98 vs. ZTS: 0.74 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ZTS' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.21  Med: 0.67 Max: 0.94
Current: 0.74
0.21
0.94
3-Year Average Share Buyback Ratio -0.10
ZTS's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 466 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -3.30 vs. ZTS: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ZTS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1  Med: -0.05 Max: 0
Current: -0.1
-0.1
0

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.30
ZTS's Price/Median PS Value is ranked lower than
59% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. ZTS: 1.30 )
Ranked among companies with meaningful Price/Median PS Value only.
ZTS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.92  Med: 1.16 Max: 1.3
Current: 1.3
0.92
1.3
Earnings Yield (Greenblatt) (%) 2.42
ZTS's Earnings Yield (Greenblatt) (%) is ranked lower than
56% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. ZTS: 2.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZTS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.4  Med: 3.80 Max: 4.8
Current: 2.42
2.4
4.8

More Statistics

Revenue(Mil) $4765
EPS $ 0.68
Beta0.99
Short Percentage of Float1.62%
52-Week Range $37.73 - 55.38
Shares Outstanding(Mil)497.16

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 4,767 5,067 5,330
EPS($) 1.78 2.25 2.60
EPS without NRI($) 1.78 2.25 2.60

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, NYSE:TEVA, TSE:4502, BOM:524715, NAS:MYL » details
Traded in other countries:ZOE.Germany,
Zoetis Inc was incorporated in Delaware in July 2012. It is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. It markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight core species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses; and five product categories: anti-infectives - products that prevent, kill or slow the growth of bacteria, fungi or protozoa; vaccines - biological preparations that help prevent diseases of the respiratory, gastrointestinal and reproductive tracts or induce a specific immune response; parasiticides - products that prevent or eliminate external and internal parasites such as fleas, ticks and worms; medicated feed additives; and other pharmaceutical products - pain and sedation, oncology, antiemetic, allergy and dermatology; and reproductive products. The Company organizes and operates its business in four segments: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific. The Company sells its livestock products directly to a diverse set of livestock producers, including beef and dairy farmers as well as pork, poultry and aquaculture operations, and to veterinarians, third-party veterinary distributors and retail outlets that typically then sell the products to livestock producers. It primarily sells its companion animal products to veterinarians or to third-party veterinary distributors that typically then sell its products to veterinarians, and in each case veterinarians then typically sell its products to pet owners. Its primary competitors include animal health medicines and vaccines companies such as Merck Animal Health, the animal health division of Merck & Co., Inc. (formerly known as Intervet/Schering-Plough); Merial, the animal health division of Sanofi S.A.; Elanco, the animal health division of Eli Lilly and Company; Bayer Animal Health, the animal health division of Bayer AG; Novartis Animal Health, the animal health division of Novartis AG; and Boehringer Ingelheim Animal Health, the animal health division of Boehringer Ingelheim GmbH. In addition, it competes with hundreds of other animal health product producers throughout the world.
» More Articles for ZTS

Headlines

Articles On GuruFocus.com
Highlights of Bill Ackman’s 1st Quarter Pershing Square Conference Call Apr 06 2016 
Bill Ackman’s Fund Falls by Double Digits Again in January Feb 02 2016 
Bill Ackman's 3rd Quarter Letter to Pershing Square Shareholders Dec 21 2015 
Bill Ackman Comments on Zoetis Inc. Dec 16 2015 
Bill Ackman's Pershing Square 3rd Quarter Letter to Shareholders Dec 16 2015 
Olstein Funds 2015 Annual Letter to Shareholders Sep 24 2015 
Bill Ackman Comments on Zoetis Inc. Sep 11 2015 
Bill Ackman's Semi-Annual 2015 Letter to Pershing Square Investors Sep 11 2015 
The Best Companies of the Pharmaceuticals Industry – August 2015 Aug 18 2015 
Acquisition in the Health Care Industry Increased Volatility Jun 27 2015 

More From Other Websites
Zoetis, Inc. :ZTS-US: Earnings Analysis: Q1, 2016 By the Numbers May 05 2016
Zoetis Shares Fall Despite Beating Estimates and Boosting Outlook May 04 2016
Edited Transcript of ZTS earnings conference call or presentation 4-May-16 12:30pm GMT May 04 2016
Zoetis (ZTS) Tops Q1 Earnings & Revenues, Updates Outlook May 04 2016
The Zacks Analyst Blog Highlights: Zoetis, McKesson, Merck, Endo International and AmerisourceBergen May 04 2016
Zoetis (ZTS) Beats Q1 Earnings and Revenue Estimates May 04 2016
Zoetis Reports First Quarter 2016 Results May 04 2016
Zoetis beats Street 1Q forecasts May 04 2016
Zoetis beats Street 1Q forecasts May 04 2016
Q1 2016 Zoetis Inc Earnings Release - Before Market Open May 04 2016
7:06 am Zoetis beats by $0.07, beats on revs; guides FY16 EPS above consensus, revs in-line; guides... May 04 2016
ZOETIS INC. Files SEC form 8-K, Results of Operations and Financial Condition May 04 2016
Zoetis Reports First Quarter 2016 Results May 04 2016
Bill Ackman Presentation Discusses Top Picks, Takes Another Shot at Herbalife May 03 2016
Drug Stocks Reporting Mid-Week: MRK, ABC, ENDP & More May 03 2016
Zoetis (ZTS): Stock Likely to Beat on Earnings in Q1 Again? May 02 2016
Zoetis and University of Surrey Launch New Digital Innovation Center to Advance Animal Health in... Apr 28 2016
Combating Infectious Diseases: First to Know and Fast to Market Apr 27 2016
A Closer Look At The Dogs We Help Care For Apr 26 2016
Jeff Smith’s Starboard Reports New Position; Bill Ackman’s Pershing Square Updates Two... Apr 25 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK